Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Deals

Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization

Fineline Cube Feb 20, 2024

Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...

Company Drug

Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Feb 20, 2024

Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...

Company Drug

ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL

Fineline Cube Feb 20, 2024

ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...

Policy / Regulatory

Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards

Fineline Cube Feb 20, 2024

The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...

Company Drug

AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC

Fineline Cube Feb 20, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...

Company Drug

Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease

Fineline Cube Feb 20, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...

Policy / Regulatory

China’s CDE Issues Guiding Principles for ADC Research and Evaluation

Fineline Cube Feb 20, 2024

China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...

Company Legal / IP Policy / Regulatory

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Fineline Cube Feb 20, 2024

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...

Company Deals

Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies

Fineline Cube Feb 19, 2024

Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Policy / Regulatory

China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...

Policy / Regulatory

GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...

Policy / Regulatory

National Health Commission Notification Signals New Poliovirus Containment Measures

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has issued a notification announcing the establishment of the National...

Policy / Regulatory

China’s NHC Approves 2023 Large Medical Equipment Configuration Licenses, Targets Cancer Treatment

Fineline Cube Feb 19, 2024

The National Health Commission (NHC) has granted approval for the Class A large medical equipment...

Company Drug

Hainan Poly Pharm Wins FDA Nod for Generic Version of UCB’s Vimpat

Fineline Cube Feb 19, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Policy / Regulatory

US Lawmakers Call for Sanctions Against WuXi AppTec and WuXi Biologics Over National Security Concerns

Fineline Cube Feb 19, 2024

US politicians have intensified their opposition to China’s biotech industry, with Congressmen and Senators sending...

Company

Novartis Begins Review of 70% Stake in Indian Unit, Strategic Options Under Consideration

Fineline Cube Feb 18, 2024

Novartis (NYSE: NVS) has initiated a review process concerning its 70.68% stake in Novartis India...

Company Medical Device

Boao Yiling Life Care Center Launches Innovative Dental Technologies Under Pilot Medical Policy

Fineline Cube Feb 18, 2024

Boao Yiling Life Care Center has successfully completed the inaugural use of a dental comprehensive...

Company Deals

Brii Biosciences Acquires VBI Vaccines’ Intellectual Property and Manufacturing Rights in Strategic Deal

Fineline Cube Feb 18, 2024

Brii Biosciences Ltd (HKG: 2137), based in China, has reached an agreement with US-based VBI...

Company

LianBio to Wind Down Operations Amid Market Challenges, Announces Special Dividend

Fineline Cube Feb 18, 2024

LianBio (OTCMKTS: LIANY), one of China’s prominent biotechnology firms, has announced plans to wind down...

Posts pagination

1 … 359 360 361 … 624

Recent updates

  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
  • Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Company

Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.